TOKYO -- U.S.-based Arch Venture Partners has launched a $3 billion venture capital fund specializing in medical technologies, one of the world's largest of its kind, with Japanese startups among its potential targets.
The new fund will add about 40 companies to its portfolio over three to four years, Arch co-founder Keith Crandell told Nikkei. It will invest capital from universities and institutional investors in emerging enterprises, with a focus on cutting-edge technology in such fields as drug development, genome editing and cell therapy.
